HHorinouchi· @HHorinouchi · X·· 2 天前评分60
正文 · 机器翻译
🆙#ESMO26 快速口头报告：#LCSM 非转移性 🔥ABBV-706：一种同类首创的 SEZ6 靶向拓扑异构酶 1 抑制剂（Top1i）-抗体偶联药物（ADC），在复发/难治性小细胞肺癌（R/R SCLC）中具有强效抗肿瘤活性 🎙️Anne C. Chiang 博士 🔢3837RO 🎯按推荐的3期剂量（1.8mg/kg，每3周一次，2L+，n=41） 🎯总体：ORR 56%，中位OS 12.4个月 🎯2L亚组（n=17）：ORR 82%，中位OS 14.3个月 🎯C3D1时 ctDNA 100%清除与更佳的PFS/OS相关 ☑️NCT05599984 🔗https://t.co/a1n3LKUDDS @OncoAlert @Larvol @myESMO @IASLC
热度 1 · 1 赞 · 0 回复 · 0 转发
会议摘要
NCT05599984NCT05599984按 - **标题 / Title：** Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors 对上
- **标题 / Title：** Study to Evaluate Adverse Events, Change in Disease Activity, and How ABBV-706 Moves Through the Body When Intravenously (IV) Infused Alone or in Combination With IV Infused Budigalimab, Cisplatin, or Carboplatin in Adult Participants With Advanced Solid Tumors读摘要原文 →来源：HHorinouchi · x.com